Login to Your Account



Affimed Raises $33.5M For TandAbs In Oncology

By Cormac Sheridan


Wednesday, April 11, 2007
Affimed Therapeutics AG raised €25 million (US$33.5 million) in a Series B round to fund its two lead programs, in non-Hodgkins lymphoma (NHL) and Hodgkin's disease. Each is in preclinical development at present. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription